This invention relates to heterocyclic red azo colorants for seed treatment applications. The red azo colorants contain a heterocycle that includes one nitrogen atom and one sulfur atom and are free from electron-withdrawing groups on the heterocycle. Seeds for use in horticultural/agriculture applications that are coated with the heterocyclic azo colorants provide anti-counterfeiting properties to the coated seeds. A color change phenomenon is observed when the coated seeds are exposed to an acidic material, such as vinegar, and provides evidence of the authenticity of the coated seeds. The invention also relates to agricultural formulations containing the heterocyclic red azo colorants that can be used as an anti-counterfeit agents.

This invention relates to heterocyclic red azo colorants for seed treatment applications. The red azo colorants contain a heterocycle that includes one nitrogen atom and one sulfur atom and are free from electron-withdrawing groups on the heterocycle. Seeds for use in horticultural/agriculture applications that are coated with the heterocyclic azo colorants provide anti-counterfeiting properties to the coated seeds. A color change phenomenon is observed when the coated seeds are exposed to an acidic material, such as vinegar, and provides evidence of the authenticity of the coated seeds. The invention also relates to agricultural formulations containing the heterocyclic red azo colorants that can be used as an anti-counterfeit agents.

The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

According to the present invention, a lens adhesive including a compound represented by General Formula 1 is provided.
Pol.sub.1-Sp.sub.1-L.sub.1-Ar-L.sub.2-Sp.sub.2-Pol.sub.2  (General Formula 1) In the formula, Ar is an aromatic ring group represented by General Formula 2-2 and the like. ##STR00001## In the formula, Z.sub.1 and Z.sub.2 each represent a hydrogen atom, a methyl group, and the like; A.sub.1 and A.sub.2 each represent —S— and the like; X represents C(Rz).sub.2 and the like (where Rz is a substituent, and two Rz's may form a ring); L.sub.1 and L.sub.2 each represent a single bond, —O—, —OC(═O)—, —OC(═O)O—, —OC(═O)NH—, and the like; Sp.sub.1 and Sp.sub.2 each represent a single bond or a linking group such as a linear alkylene group; Pol.sub.1 and Pol.sub.2 each represent a hydrogen atom or a polymerizable group; and a compound represented by General Formula 1 has at least one polymerizable group. Using the lens adhesive, it is possible to provide a cemented lens that is unlikely to deteriorate due to light, and an imaging module having high durability.

According to the present invention, a lens adhesive including a compound represented by General Formula 1 is provided.
Pol.sub.1-Sp.sub.1-L.sub.1-Ar-L.sub.2-Sp.sub.2-Pol.sub.2  (General Formula 1) In the formula, Ar is an aromatic ring group represented by General Formula 2-2 and the like. ##STR00001## In the formula, Z.sub.1 and Z.sub.2 each represent a hydrogen atom, a methyl group, and the like; A.sub.1 and A.sub.2 each represent —S— and the like; X represents C(Rz).sub.2 and the like (where Rz is a substituent, and two Rz's may form a ring); L.sub.1 and L.sub.2 each represent a single bond, —O—, —OC(═O)—, —OC(═O)O—, —OC(═O)NH—, and the like; Sp.sub.1 and Sp.sub.2 each represent a single bond or a linking group such as a linear alkylene group; Pol.sub.1 and Pol.sub.2 each represent a hydrogen atom or a polymerizable group; and a compound represented by General Formula 1 has at least one polymerizable group. Using the lens adhesive, it is possible to provide a cemented lens that is unlikely to deteriorate due to light, and an imaging module having high durability.

Provided herein are small molecule inhibitors of NSD1, NSD2 and/or NSD3 activity, and methods of use thereof for the treatment of disease, including leukemia, breast cancer, osteosarcoma, lung and prostate cancers and other solid tumors as well as other diseases dependent on the activity of NSD1, NSD2 and/or NSD3.

Substances and methods are dislosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole.